ABBOTT LABORATORIES (ABT) FY2026 Q1 Balance Sheet

ABBOTT LABORATORIES (ABT) FY2026 Q1 Balance Sheet

Balance sheet as of 2026-03-31. The chart shows assets, liabilities and equity at that date.

Assets

110,429,000,000 US dollars

Current assets

25,508,000,000 US dollars

Non-current assets

84,921,000,000 US dollars

Liabilities (calculated)

57,728,000,000 US dollars

Current liabilities

18,377,000,000 US dollars

Non-current liabilities

39,351,000,000 US dollars

Equity

52,701,000,000 US dollars

Noncontrolling interest

640,000,000 US dollars. Included in consolidated equity; this amount is not added again.

Property and equipment, at cost

25,737,000,000 US dollars. Part of Net property and equipment, drawn as one net amount.

Less: accumulated depreciation and amortization

negative 13,360,000,000 US dollars. Part of Net property and equipment, drawn as one net amount.

Trade receivables, less allowances of $494 in 2026 and $490 in 2025

8,210,000,000 US dollars

Cash and cash equivalents

6,803,000,000 US dollars

Finished products

4,274,000,000 US dollars

Prepaid expenses and other receivables

3,014,000,000 US dollars

Materials

1,721,000,000 US dollars

Work in process

994,000,000 US dollars

Short-term investments

492,000,000 US dollars

Goodwill

35,221,000,000 US dollars

Deferred income taxes and other assets

18,358,000,000 US dollars

Intangible assets, net of amortization

17,875,000,000 US dollars

Net property and equipment

12,377,000,000 US dollars

Investments

1,090,000,000 US dollars

Other accrued liabilities

6,379,000,000 US dollars

Trade accounts payable

4,679,000,000 US dollars

Current portion of long-term debt

4,409,000,000 US dollars

Salaries, wages, and commissions

1,212,000,000 US dollars

Dividends payable

1,100,000,000 US dollars

Income taxes payable

598,000,000 US dollars

Long-term debt

29,638,000,000 US dollars

Post-employment obligations, deferred income taxes, and other long-term liabilities

9,713,000,000 US dollars

Earnings employed in the business

49,956,000,000 US dollars

Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2026: 1,998,233,756; 2025: 1,996,795,525

25,352,000,000 US dollars

Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued

0 US dollars

Noncontrolling interests

640,000,000 US dollars

Common shares held in treasury, at cost — Shares: 2026: 256,420,602; 2025: 260,196,074

negative 16,935,000,000 US dollars

Accumulated other comprehensive income (loss)

negative 6,312,000,000 US dollars

Gross equity (calculated)

75,948,000,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

• Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
• Treasury shares and other negative equity contributions reduce equity.